ADA: GLP-1 Receptor Agonist Use Beneficial in Adults With Obesity, Autoimmune Disease MONDAY, June 8, 2026 -- Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with reduced risks for thromboembolic events, emergency department use, and mortality among adults with obesity and autoimmune diseases (AIDs), according to a study published online June 6 in the Journal of the American Heart Association to coincide with the annual meeting of the American Diabetes Association, held from June 5 to 8 in New Orleans
doi: 10.1016/j.cca.2019.12.009 23
References Virani, S
Weight loss : Retatrutide showed 28.7% at 68 weeks (Phase 3 TRIUMPH-4) versus CagriSema's 20.4% at 68 weeks (Phase 3 REDEFINE 1), though cross-trial comparisons are limited
Q: When is the ideal time to consume these tablets
Studies that score 15 will be considered low quality, while scores 610 will be considered high quality. The Grading of Recommendations Assessment, Development, and Evaluation Working Group methodology (GRADE) [19] will be used to classify the certainty of evidence